Xiao-ming Zhang

Xiao-ming Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
YYYing Yuan
Ying Yuan
YTYuan Tian
Yuan Tian
HJHui Jiang
Hui Jiang
LCLuo-Yang Cai
Luo-Yang Cai
JSJie Song
Jie Song
XZXiao-ming Zhang
Xiao-ming Zhang
Cerebral ischemia–reperfusion injury (CIRI) is a series of cascade reactions that occur after blood flow recanalization in the ischemic zone in patients with cerebral infarction, causing an imbalance in intracellular homeostasis through multiple pathologies such as increased oxygen free radicals, inflammatory response, calcium overload, and impaired energy metabolism, leading to mitochondrial dysfunction and ultimately apoptosis. Rescue of reversibly damaged neurons in the ischemic hemispheric zone is the key to saving brain infarction and reducing neurological deficits. Complex and active neurological functions are highly dependent on an adequate energy supply from mitochondria. Mitochondrial biogenesis (MB), a process that generates new functional mitochondria and restores normal mitochondrial function by replacing damaged mitochondria, is a major mechanism for maintaining intra-mitochondrial homeostasis and is involved in mitochondrial quality control to ameliorate mitochondrial dysfunction and thus protects against CIRI. The main regulator of MB is peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), which improves mitochondrial function to protect against CIRI by activating its downstream nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM) to promote mitochondrial genome replication and transcription. This paper provides a theoretical reference for the treatment of neurological impairment caused by CIRI by discussing the mechanisms of mitochondrial biogenesis during cerebral ischemia–reperfusion injury.

2 July 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
XRXiaofeng Ruan
Xiaofeng Ruan
XZXiao-ming Zhang
Xiao-ming Zhang
LLLiming Liu
Liming Liu
JZJianjun Zhang
Jianjun Zhang
Xiaoyao san (XYS) plays an important role in treatment of non-alcoholic fatty liver disease (NAFLD) with liver stagnation and spleen deficiency, but its specific mechanism is still unclear. This study aimed to investigate the material basis and mechanism by means of network pharmacology, metabolomics, systems biology and molecular docking methods. On this basis, NAFLD rat model with liver stagnation and spleen deficiency was constructed and XYS was used to intervene, and liver histopathology, biochemical detection, enzyme-linked immunosorbent assay, quantitative PCR assay and western blotting were used to further verify the mechanism. Through the above research methods, network pharmacology study showed that there were 94 targets in total for XYS in the treatment of NAFLD. Metabolomics study showed that NAFLD with liver depression and spleen deficiency had a total of 73 differential metabolites. Systems biology found that PTGS2 and PPARG were the core targets; Quercetin, kaempferol, naringenin, beta-sitosterol and stigmasterol were the core active components; AA, cAMP were the core metabolites. And molecular docking showed that the core active components can act well on the key targets. Animal experiments showed that XYS could improve liver histopathology, increase 5HT and NA, decrease INS and FBG, improve blood lipids and liver function, decrease AA, increase cAMP, down-regulate PTGS2, up-regulate PPARG, and decrease PGE2 and 15d-PGJ2. In conclusion, XYS might treat NAFLD with liver depression and spleen deficiency by down-regulating PTGS2, up-regulating PPARG, reducing AA content, increasing cAMP, improving insulin resistance, affecting glucose and lipid metabolism, inhibiting oxidative stress and inflammatory response.Communicated by Ramaswamy H. Sarma.

20 March 2025 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
LCLuo-Yang Cai
Luo-Yang Cai
YYYing Yuan
Ying Yuan
HHHai Huang
Hai Huang
JZJin Zhang
Jin Zhang
XZXin-Yi Zou
Xin-Yi Zou
XZXiao-ming Zhang
Xiao-ming Zhang
Cerebral ischemia-reperfusion injury (CIRI) is a complex pathophysiological process faced by brain tissues after ischemic stroke treatment, which involves mechanisms of inflammatory response, oxidative stress and apoptosis, and severely affects treatment outcome. Lipocalin-2 (LCN2), an acute-phase protein, is significantly up-regulated after CIRI and promotes neural repair by enhancing astrocyte phagocytosis, but its over-activation may also trigger secondary inflammation and demyelination injury. LCN2 also plays a key role in neuroinflammation regulation by regulating the polarization state of astrocytes and the release of inflammatory factors, and may affect the integrity of the blood–brain barrier and a variety of pathologic injury processes. In view of the important role of LCN2 in CIRI, this article reviews the mechanism of LCN2, aiming to provide new ideas and methods for the treatment of ischemic stroke.

23 November 2022 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
YYYing Yuan
Ying Yuan
XZXiao-ming Zhang
Xiao-ming Zhang

1 January 2021 in Experimental Animals
Verified
Journal Article
Open access
PDF file
DZDan Zhou
Dan Zhou
FYFeng Yang
Feng Yang
LLLing Lin
Ling Lin
LTLi Tang
Li Tang
LLLongjiang Li
Longjiang Li
LZLi Zhang
Li Zhang
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

27 March 2025 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
JZJin Zhang
Jin Zhang
XPXiang Peng
Xiang Peng
MLMan Li
Man Li
XZXiao-ming Zhang
Xiao-ming Zhang
HXHong-Chun Xiang
Hong-Chun Xiang